Attached files
file | filename |
---|---|
EX-99.1 - ZIOPHARM ONCOLOGY INC | v209012_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): January 20, 2011
ZIOPHARM
Oncology, Inc.
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
001-33038
|
84-1475642
|
||
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
1180
Avenue of the Americas
19th
Floor
New
York, NY
|
10036
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(646) 214-0700
(Registrant’s
telephone number, including area code)
Not
applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following
provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425).
|
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12).
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b)).
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c)).
|
|
|
Item
8.01 Other Events.
On
January 20, 2011, ZIOPHARM Oncology, Inc. (the “Company”) issued a press release
announcing that The Committee for Orphan Medicinal Products within the European
Medicines Agency adopted a positive opinion for the designation of darinaparsin'
(Zinapar™ or ZIO-101) as an orphan medicinal product for the treatment of
peripheral T-cell lymphoma. A copy of the above referenced press release is
filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein
by reference.
Item
9.01
|
Financial
Statements and Exhibits.
|
||
(d)
|
Exhibits
|
||
Exhibit No.
|
Description
|
||
99.1
|
Press
Release dated January 20, 2011
|
||
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
ZIOPHARM
Oncology, Inc.
|
||
By:
|
/s/
Richard Bagley
|
|
Date:
January 26, 2011
|
Name:
Richard Bagley
|
|
Title:
President, Chief Operating Officer and Chief Financial
Officer
|
INDEX OF
EXHIBITS
Exhibit No.
|
Description
|
|
99.1
|
Press
Release dated January 20, 2011
|